Sartori Ana Marli Christovam, Vicentine Margarete Paganotti, Gryninger Lígia Castelloni Figueiredo, Soárez Patricia Coelho de, Novaes Hillegonda Maria Dutilh
Rev Saude Publica. 2015;49:8. doi: 10.1590/s0034-8910.2015049005492. Epub 2015 Feb 27.
OBJECTIVE To analyze the costs of vaccination regimens for introducing inactivated polio vaccine in routine immunization in Brazil. METHODS A cost analysis was conducted for vaccines in five vaccination regimens, including inactivated polio vaccine, compared with the oral polio vaccine-only regimen. The costs of the vaccines were estimated for routine use and for the "National Immunization Days", during when the oral polio vaccine is administered to children aged less than five years, independent of their vaccine status, and the strategic stock of inactivated polio vaccine. The presented estimated costs are of 2011. RESULTS The annual costs of the oral vaccine-only program (routine and two National Immunization Days) were estimated at US$19,873,170. The incremental costs of inclusion of the inactivated vaccine depended on the number of vaccine doses, presentation of the vaccine (bottles with single dose or ten doses), and number of "National Immunization Days" carried out. The cost of the regimen adopted with two doses of inactivated vaccine followed by three doses of oral vaccine and one "National Immunization Day" was estimated at US$29,653,539. The concomitant replacement of the DTPw/Hib and HepB vaccines with the pentavalent vaccine enabled the introduction of the inactivated polio without increasing the number of injections or number of visits needed to complete the vaccination. CONCLUSIONS The introduction of the inactivated vaccine increased the annual costs of the polio vaccines by 49.2% compared with the oral vaccine-only regimen. This increase represented 1.13% of the expenditure of the National Immunization Program on the purchase of vaccines in 2011.
目的 分析在巴西将灭活脊髓灰质炎疫苗引入常规免疫接种计划的成本。方法 针对五种疫苗接种方案(包括灭活脊髓灰质炎疫苗)进行成本分析,并与仅使用口服脊髓灰质炎疫苗的方案进行比较。估算了疫苗用于常规接种以及在“全国免疫日”(即在该日对5岁以下儿童(无论其疫苗接种状况如何)接种口服脊髓灰质炎疫苗)时的成本,以及灭活脊髓灰质炎疫苗的战略储备成本。所呈现的估算成本为2011年的成本。结果 仅使用口服疫苗的方案(常规接种和两个全国免疫日)的年度成本估计为19873170美元。纳入灭活疫苗的增量成本取决于疫苗剂量、疫苗剂型(单剂量瓶或十剂量瓶)以及开展的“全国免疫日”数量。采用两剂灭活疫苗后接三剂口服疫苗和一个“全国免疫日”的方案成本估计为29653539美元。用五价疫苗同时替代白喉、破伤风、百日咳和b型流感嗜血杆菌结合疫苗以及乙肝疫苗,使得在不增加注射次数或完成接种所需就诊次数的情况下能够引入灭活脊髓灰质炎疫苗。结论 与仅使用口服疫苗的方案相比,引入灭活疫苗使脊髓灰质炎疫苗的年度成本增加了49.2%。这一增加额占2011年国家免疫计划疫苗采购支出的1.13%。